Dr. James Karlowsky

Professor, Department of Medical Microbiology and Infectious Disease, Faculty of Medicine, University of Manitoba
Director, Clinical Microbiology Fellowship Training Program, Faculty of Medicine, University of Manitoba
Clinical Microbiologist, Diagnostic Services of Manitoba/St. Boniface Hospital

Degrees: B.Sc.[Pharmacy] (Manitoba , 1991),
Ph.D.[Medical Microbiology] (Manitoba , 1996),

Postdoctoral Fellowships: Pharmacy (Manitoba , 1998), Medical Microbiology (Iowa , 2005)

Professional Certifications/Awarded Fellowships:
D[ABMM] (2005), FIDSA (2007)

Mailing Address: Department of Clinical Microbiology, St. Boniface Hospital, 409 Tache Avenue, L4025-9,
Winnipeg, Manitoba, R2H 2A6, Canada

Tel: (204) 237-2125,  Fax: (204) 237-7678
E-mail: jkarlowsky@dsmanitoba.ca

Research Interests:
Antimicrobial resistance; diagnostic clinical microbiology

Recent Publications:

  1. Manickam K, Karlowsky JA, Adam HJ, Lagacé-Wiens PRS, Rendina A, Pang P, Murray BL, Alfa MJ. CHROMagar™ Orientation media reduces urine culture workload. Journal of Clinical Microbiology, 2013;51(4):1179-1183
  2. Walkty A, Lagacé-Wiens PRS, Manickam K, Adam HJ, Pieroni P, Hoban DJ, Karlowsky JA, Alfa MJ. Laboratory diagnosis of Clostridium difficile infection – evaluation of an algorithmic approach in comparison with the Illumigene® assay. Journal of Clinical Microbiology, 2013;51(4):1152-1157.
  3. Karlowsky JA, Adam HJ,Desjardins M,Lagacé-Wiens PRS, Hoban DJ, Zhanel GG. Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals. Journal of Antimicrobial Chemotherapy, 2013;68(Supplement 1):i39-i46
  4. Zhanel GG, Lawson C, Zelenitsky S, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. Ceftazidime-avibactam, a new antimicrobial agent with potent activity against gram-negative bacteria frequently causing human infections.Drugs, 2013;73(2):159-177.
  5. Al-Juaid A, Walkty A, Embil JE, Crockett M, Karlowsky JA. Differential time to positivity: vascular catheter drawn cultures for the determination of catheter-related bloodstream infection. Scandinavian Journal of Infectious Disease, 2012;44(10):721-725.
  6. Walkty A, Lagacé-Wiens PRS, Manickam K, Adam H, Pieroni P, Alfa MA, Karlowsky JA. Re-evaluation of rejection criteria for endotracheal tube (ETT) specimens from adult patients. Journal of Medical Microbiology, 2012;61(9):1306-1310
  7. Zhanel GG, Yachison C, Nichol KA, Adam HA, Noreddin AM, Hoban DJ, Karlowsky JA. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs to ceftaroline using an in vitro pharmacodynamics model. Journal of Antimicrobial Chemotherapy, 2012;67(7):1706-1711.
  8. Karlowsky JA, Zhanel GG, Hammond G, Rubinstein E, Wiley J, Du T, Mulvey MR, Alfa MJ. Multidrug-resistant, NAP2 Clostridium difficile were the predominant toxigenic, hospital-acquired strain in Manitoba, Canada when mandatory reporting started in 2006. Journal of Medical Microbiology, 2012;61(5):693-700.
  9. Karlowsky JA, Walkty A, Adam HJ, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.  Antimicrobial Agents and Chemotherapy, 2012;56(3):1247-1252.
  10. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clinical Infectious Diseases, 2012;54(Supplement 3):S214-S219.

    11. NOT ACCEPTING GRADUATE STUDENTS AT THIS TIME